RNA vs. TVTX, DICE, SNDX, MORF, ARVN, CVAC, VRNA, RCKT, KDNY, and RCUS
Should you be buying Avidity Biosciences stock or one of its competitors? The main competitors of Avidity Biosciences include Travere Therapeutics (TVTX), DICE Therapeutics (DICE), Syndax Pharmaceuticals (SNDX), Morphic (MORF), Arvinas (ARVN), CureVac (CVAC), Verona Pharma (VRNA), Rocket Pharmaceuticals (RCKT), Chinook Therapeutics (KDNY), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical preparations" industry.
Avidity Biosciences vs.
Travere Therapeutics (NASDAQ:TVTX) and Avidity Biosciences (NASDAQ:RNA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.
In the previous week, Avidity Biosciences had 7 more articles in the media than Travere Therapeutics. MarketBeat recorded 12 mentions for Avidity Biosciences and 5 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.11 beat Avidity Biosciences' score of 0.11 indicating that Travere Therapeutics is being referred to more favorably in the media.
Travere Therapeutics has a net margin of -131.35% compared to Avidity Biosciences' net margin of -1,886.33%. Avidity Biosciences' return on equity of -40.82% beat Travere Therapeutics' return on equity.
Avidity Biosciences has lower revenue, but higher earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks.
Travere Therapeutics currently has a consensus price target of $32.91, indicating a potential upside of 46.33%. Avidity Biosciences has a consensus price target of $43.60, indicating a potential upside of 184.04%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Avidity Biosciences is more favorable than Travere Therapeutics.
Avidity Biosciences received 90 more outperform votes than Travere Therapeutics when rated by MarketBeat users. Likewise, 63.45% of users gave Avidity Biosciences an outperform vote while only 49.30% of users gave Travere Therapeutics an outperform vote.
Summary
Avidity Biosciences beats Travere Therapeutics on 12 of the 16 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Avidity Biosciences Competitors List